<!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-2004-03-09.dtd" [ ]>
<sequence-cwu id="SEQLST-1">
<publication-reference>
<document-id>
<country>US</country>
<doc-number>08623366</doc-number>
<kind>B2</kind>
<date>20140107</date>
</document-id>
</publication-reference>
<number>1</number>
<sequence-list-new-rules>
<s100>
<s160>39</s160>
</s100>
<s200>
<s210>1</s210>
<s211>122</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 heavy chain
      variable region</s223>
</s220>
</s200>
<s400> 1
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30
Trp Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Glu Ile Arg Ser Glu Ser Asp Ala Ser Ala Thr His Tyr Ala Glu
    50                  55                  60
Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
65                  70                  75                  80
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
                85                  90                  95
Tyr Cys Leu Ala Tyr Phe Asp Tyr Gly Leu Ala Ile Gln Asn Tyr Trp
            100                 105                 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser
        115                 120
</s400>
<s200>
<s210>2</s210>
<s211>107</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 light chain
      variable region</s223>
</s220>
</s200>
<s400> 2
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1               5                   10                  15
Glu Arg Ala Thr Leu Ser Cys Lys Ala Ser Lys Arg Val Thr Thr Tyr
            20                  25                  30
Val Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45
Tyr Gly Ala Ser Asn Arg Tyr Leu Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80
Glu Asp Phe Ala Val Tyr Tyr Cys Ser Gln Ser Tyr Asn Tyr Pro Tyr
                85                  90                  95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
            100                 105
</s400>
<s200>
<s210>3</s210>
<s211>10</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 CDR H1</s223>
</s220>
</s200>
<s400> 3
Gly Phe Thr Phe Ser Asn Tyr Trp Ile Ser
1               5                   10
</s400>
<s200>
<s210>4</s210>
<s211>19</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 CDR H2</s223>
</s220>
</s200>
<s400> 4
Glu Ile Arg Ser Glu Ser Asp Ala Ser Ala Thr His Tyr Ala Glu Ala
1               5                   10                  15
Val Lys Gly
</s400>
<s200>
<s210>5</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 CDR H3</s223>
</s220>
</s200>
<s400> 5
Tyr Phe Asp Tyr Gly Leu Ala Ile Gln Asn Tyr
1               5                   10
</s400>
<s200>
<s210>6</s210>
<s211>11</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 CDR L1</s223>
</s220>
</s200>
<s400> 6
Lys Ala Ser Lys Arg Val Thr Thr Tyr Val Ser
1               5                   10
</s400>
<s200>
<s210>7</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 CDR L2</s223>
</s220>
</s200>
<s400> 7
Gly Ala Ser Asn Arg Tyr Leu
1               5
</s400>
<s200>
<s210>8</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 CDR L3</s223>
</s220>
</s200>
<s400> 8
Ser Gln Ser Tyr Asn Tyr Pro Tyr Thr
1               5
</s400>
<s200>
<s210>9</s210>
<s211>366</s211>
<s212>DNA</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic oligonucleotide, Antibody G1 heavy
      chain variable region</s223>
</s220>
</s200>
<s400> 9
gaagttcagc tggttgaatc cggtggtggt ctggttcagc caggtggttc cctgcgtctg     60
tcctgcgctg cttccggttt caccttctcc aactactgga tctcctgggt tcgtcaggct    120
cctggtaaag gtctggaatg ggttgctgaa atccgttccg aatccgacgc gtccgctacc    180
cattacgctg aagctgttaa aggtcgtttc accatctccc gtgacaacgc taagaactcc    240
ctgtacctgc agatgaactc cctgcgtgct gaagacaccg ctgtttacta ctgcctggct    300
tactttgact acggtctggc tatccagaac tactggggtc agggtaccct ggttaccgtt    360
tcctcc                                                               366
</s400>
<s200>
<s210>10</s210>
<s211>321</s211>
<s212>DNA</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic oligonucleotide, Antibody G1 light
      chain variable region</s223>
</s220>
</s200>
<s400> 10
gaaatcgttc tgacccagtc cccggctacc ctgtccctgt ccccaggtga acgtgctacc     60
ctgtcctgca aagcttccaa acgggttacc acctacgttt cctggtacca gcagaaaccc    120
ggtcaggctc ctcgtctgct gatctacggt gcttccaacc gttacctcgg tatcccagct    180
cgtttctccg gttccggttc cggtaccgac ttcaccctga ccatctcctc cctggaaccc    240
gaagacttcg ctgtttacta ctgcagtcag tcctacaact acccctacac cttcggtcag    300
ggtaccaaac tggaaatcaa a                                              321
</s400>
<s200>
<s210>11</s210>
<s211>448</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 heavy chain</s223>
</s220>
</s200>
<s400> 11
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1               5                   10                  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
            20                  25                  30
Trp Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
        35                  40                  45
Ala Glu Ile Arg Ser Glu Ser Asp Ala Ser Ala Thr His Tyr Ala Glu
    50                  55                  60
Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser
65                  70                  75                  80
Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
                85                  90                  95
Tyr Cys Leu Ala Tyr Phe Asp Tyr Gly Leu Ala Ile Gln Asn Tyr Trp
            100                 105                 110
Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
        115                 120                 125
Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr
    130                 135                 140
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
145                 150                 155                 160
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
                165                 170                 175
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
            180                 185                 190
Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp
        195                 200                 205
His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys Cys
    210                 215                 220
Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser
225                 230                 235                 240
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
                245                 250                 255
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
            260                 265                 270
Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
        275                 280                 285
Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val
    290                 295                 300
Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
305                 310                 315                 320
Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr
                325                 330                 335
Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
            340                 345                 350
Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys
        355                 360                 365
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
    370                 375                 380
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp
385                 390                 395                 400
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
                405                 410                 415
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
            420                 425                 430
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
        435                 440                 445
</s400>
<s200>
<s210>12</s210>
<s211>214</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 light chain</s223>
</s220>
</s200>
<s400> 12
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1               5                   10                  15
Glu Arg Ala Thr Leu Ser Cys Lys Ala Ser Lys Arg Val Thr Thr Tyr
            20                  25                  30
Val Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
        35                  40                  45
Tyr Gly Ala Ser Asn Arg Tyr Leu Gly Ile Pro Ala Arg Phe Ser Gly
    50                  55                  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65                  70                  75                  80
Glu Asp Phe Ala Val Tyr Tyr Cys Ser Gln Ser Tyr Asn Tyr Pro Tyr
                85                  90                  95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
            100                 105                 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
        115                 120                 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
    130                 135                 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145                 150                 155                 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
                165                 170                 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
            180                 185                 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
        195                 200                 205
Phe Asn Arg Gly Glu Cys
    210
</s400>
<s200>
<s210>13</s210>
<s211>1347</s211>
<s212>DNA</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic oligonucleotide, Antibody G1 heavy
      chain</s223>
</s220>
</s200>
<s400> 13
gaagttcagc tggttgaatc cggtggtggt ctggttcagc caggtggttc cctgcgtctg     60
tcctgcgctg cttccggttt caccttctcc aactactgga tctcctgggt tcgtcaggct    120
cctggtaaag gtctggaatg ggttgctgaa atccgttccg aatccgacgc gtccgctacc    180
cattacgctg aagctgttaa aggtcgtttc accatctccc gtgacaacgc taagaactcc    240
ctgtacctgc agatgaactc cctgcgtgct gaagacaccg ctgtttacta ctgcctggct    300
tactttgact acggtctggc tatccagaac tactggggtc agggtaccct ggttaccgtt    360
tcctccgcct ccaccaaggg cccatctgtc ttcccactgg ccccatgctc ccgcagcacc    420
tccgagagca cagccgccct gggctgcctg gtcaaggact acttcccaga acctgtgacc    480
gtgtcctgga actctggcgc tctgaccagc ggcgtgcaca ccttcccagc tgtcctgcag    540
tcctcaggtc tctactccct cagcagcgtg gtgaccgtgc catccagcaa cttcggcacc    600
cagacctaca cctgcaacgt agatcacaag ccaagcaaca ccaaggtcga caagaccgtg    660
gagagaaagt gttgtgtgga gtgtccacct tgtccagccc ctccagtggc cggaccatcc    720
gtgttcctgt tccctccaaa gccaaaggac accctgatga tctccagaac cccagaggtg    780
acctgtgtgg tggtggacgt gtcccacgag gacccagagg tgcagttcaa ctggtatgtg    840
gacggagtgg aggtgcacaa cgccaagacc aagccaagag aggagcagtt caactccacc    900
ttcagagtgg tgagcgtgct gaccgtggtg caccaggact ggctgaacgg aaaggagtat    960
aagtgtaagg tgtccaacaa gggactgcca tccagcatcg agaagaccat ctccaagacc   1020
aagggacagc caagagagcc acaggtgtat accctgcccc catccagaga ggagatgacc   1080
aagaaccagg tgtccctgac ctgtctggtg aagggattct atccatccga catcgccgtg   1140
gagtgggagt ccaacggaca gccagagaac aactataaga ccacccctcc aatgctggac   1200
tccgacggat ccttcttcct gtattccaag ctgaccgtgg acaagtccag atggcagcag   1260
ggaaacgtgt tctcttgttc cgtgatgcac gaggccctgc acaaccacta tacccagaag   1320
agcctgtccc tgtctccagg aaagtaa                                       1347
</s400>
<s200>
<s210>14</s210>
<s211>645</s211>
<s212>DNA</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic oligonucleotide, Antibody G1 light
      chain</s223>
</s220>
</s200>
<s400> 14
gaaatcgttc tgacccagtc cccggctacc ctgtccctgt ccccaggtga acgtgctacc     60
ctgtcctgca aagcttccaa acgggttacc acctacgttt cctggtacca gcagaaaccc    120
ggtcaggctc ctcgtctgct gatctacggt gcttccaacc gttacctcgg tatcccagct    180
cgtttctccg gttccggttc cggtaccgac ttcaccctga ccatctcctc cctggaaccc    240
gaagacttcg ctgtttacta ctgcagtcag tcctacaact acccctacac cttcggtcag    300
ggtaccaaac tggaaatcaa acgcactgtg gctgcaccat ctgtcttcat cttccctcca    360
tctgatgagc agttgaaatc cggaactgcc tctgttgtgt gcctgctgaa taacttctat    420
ccgcgcgagg ccaaagtaca gtggaaggtg gataacgccc tccaatccgg taactcccag    480
gagagtgtca cagagcagga cagcaaggac agcacctaca gcctcagcag caccctgacc    540
ctgagcaaag cagactacga gaaacacaaa gtctacgcct gcgaagtcac ccatcagggc    600
ctgagttctc cagtcacaaa gagcttcaac cgcggtgagt gctaa                    645
</s400>
<s200>
<s210>15</s210>
<s211>37</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
<s220>
<s223>Polypeptide, Alpha-CGRP</s223>
</s220>
</s200>
<s400> 15
Ala Cys Asp Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu
1               5                   10                  15
Ser Arg Ser Gly Gly Val Val Lys Asn Asn Phe Val Pro Thr Asn Val
            20                  25                  30
Gly Ser Lys Ala Phe
        35
</s400>
<s200>
<s210>16</s210>
<s211>37</s211>
<s212>PRT</s212>
<s213>Homo sapiens</s213>
<s220>
<s223>Polypeptide, Beta-CGRP</s223>
</s220>
</s200>
<s400> 16
Ala Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu
1               5                   10                  15
Ser Arg Ser Gly Gly Met Val Lys Ser Asn Phe Val Pro Thr Asn Val
            20                  25                  30
Gly Ser Lys Ala Phe
        35
</s400>
<s200>
<s210>17</s210>
<s211>37</s211>
<s212>PRT</s212>
<s213>Rattus norvegicus</s213>
<s220>
<s223>Polypeptide, Alpha-CGRP</s223>
</s220>
</s200>
<s400> 17
Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu
1               5                   10                  15
Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val
            20                  25                  30
Gly Ser Glu Ala Phe
        35
</s400>
<s200>
<s210>18</s210>
<s211>37</s211>
<s212>PRT</s212>
<s213>Rattus norvegicus</s213>
<s220>
<s223>Polypeptide, Beta-CGRP</s223>
</s220>
</s200>
<s400> 18
Ser Cys Asn Thr Ala Thr Cys Val Thr His Arg Leu Ala Gly Leu Leu
1               5                   10                  15
Ser Arg Ser Gly Gly Val Val Lys Asp Asn Phe Val Pro Thr Asn Val
            20                  25                  30
Gly Ser Lys Ala Phe
        35
</s400>
<s200>
<s210>19</s210>
<s211>115</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 heavy chain
      variable region</s223>
</s220>
</s200>
<s400> 19
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1               5                   10                  15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser
            20                  25                  30
Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60
Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80
Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Gly Gly Asn Asp Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr
            100                 105                 110
Val Ser Ser
        115
</s400>
<s200>
<s210>20</s210>
<s211>108</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 light chain
      variable region</s223>
</s220>
</s200>
<s400> 20
Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly
1               5                   10                  15
Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Ile
            20                  25                  30
Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Val Leu
        35                  40                  45
Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
    50                  55                  60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu
65                  70                  75                  80
Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Thr Ile Pro
                85                  90                  95
Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
            100                 105
</s400>
<s200>
<s210>21</s210>
<s211>5</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 Kabat CDR H1</s223>
</s220>
</s200>
<s400> 21
Ser Ser Val Met His
1               5
</s400>
<s200>
<s210>22</s210>
<s211>17</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 CDR H2</s223>
</s220>
</s200>
<s400> 22
Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys
1               5                   10                  15
Gly
</s400>
<s200>
<s210>23</s210>
<s211>6</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 CDR H3</s223>
</s220>
</s200>
<s400> 23
Gly Gly Asn Asp Gly Tyr
1               5
</s400>
<s200>
<s210>24</s210>
<s211>12</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 CDR L1</s223>
</s220>
</s200>
<s400> 24
Ser Ala Ser Ser Ser Ile Ser Ser Ile Tyr Leu His
1               5                   10
</s400>
<s200>
<s210>25</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 CDR L2</s223>
</s220>
</s200>
<s400> 25
Arg Ala Ser Asn Leu Ala Ser
1               5
</s400>
<s200>
<s210>26</s210>
<s211>9</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 CDR L3</s223>
</s220>
</s200>
<s400> 26
Gln Gln Gly Ser Thr Ile Pro Phe Thr
1               5
</s400>
<s200>
<s210>27</s210>
<s211>345</s211>
<s212>DNA</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic oligonucleotide, Antibody G2 heavy
      chain variable region</s223>
</s220>
</s200>
<s400> 27
gaggtccagc tgcagcagtc tggacctgag ctggtaaagc ctggggcttc agtgaagatg     60
tcctgcaagg cttctggata cacattcact agctctgtta tgcactgggt gaagcagaag    120
cctgggcagg gccttgagtg gattggatat attaatcctt acaatgatgg tactaagtac    180
aatgagaagt tcaaaggcaa ggccacactg acttcagaca aatcctccag cacagcctac    240
atggaactca gcagcctgac ctctgaggac tctgcggtct attactgtgc aaaagggggt    300
aacgatggct actggggcca aggcactact ctcacagtct cctca                    345
</s400>
<s200>
<s210>28</s210>
<s211>324</s211>
<s212>DNA</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic oligonucleotide, Antibody G2 light
      chain variable region</s223>
</s220>
</s200>
<s400> 28
gaaattgtgc tcacccagtc tccaaccacc atggctgcat ctcccgggga gaagatcact     60
atcacctgta gtgccagctc aagtataagt tccatttact tgcattggta tcagcagaag    120
ccaggattct cccctaaagt cttgatttat agggcatcca atctggcttc tggagtccca    180
gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaattgg caccatggag    240
gctgaagatg ttgccactta ctactgccag cagggtagta ctataccatt cacgttcggc    300
tcggggacaa agttggaaat aaaa                                           324
</s400>
<s200>
<s210>29</s210>
<s211>216</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 heavy chain</s223>
</s220>
</s200>
<s400> 29
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1               5                   10                  15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Ser
            20                  25                  30
Val Met His Trp Val Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp Ile
        35                  40                  45
Gly Tyr Ile Asn Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe
    50                  55                  60
Lys Gly Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala Tyr
65                  70                  75                  80
Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
                85                  90                  95
Ala Lys Gly Gly Asn Asp Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr
            100                 105                 110
Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro
        115                 120                 125
Gly Ser Ala Ala Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val
    130                 135                 140
Lys Gly Tyr Phe Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser
145                 150                 155                 160
Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu
                165                 170                 175
Tyr Thr Leu Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser
            180                 185                 190
Glu Thr Val Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val
        195                 200                 205
Asp Lys Lys Ile Val Pro Arg Asp
    210                 215
</s400>
<s200>
<s210>30</s210>
<s211>215</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 light chain</s223>
</s220>
</s200>
<s400> 30
Glu Ile Val Leu Thr Gln Ser Pro Thr Thr Met Ala Ala Ser Pro Gly
1               5                   10                  15
Glu Lys Ile Thr Ile Thr Cys Ser Ala Ser Ser Ser Ile Ser Ser Ile
            20                  25                  30
Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Phe Ser Pro Lys Val Leu
        35                  40                  45
Ile Tyr Arg Ala Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser
    50                  55                  60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Gly Thr Met Glu
65                  70                  75                  80
Ala Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Gly Ser Thr Ile Pro
                85                  90                  95
Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp Ala
            100                 105                 110
Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser
        115                 120                 125
Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Arg Asp
    130                 135                 140
Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val
145                 150                 155                 160
Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met
                165                 170                 175
Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser
            180                 185                 190
Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys
        195                 200                 205
Ser Phe Asn Arg Asn Glu Cys
    210                 215
</s400>
<s200>
<s210>31</s210>
<s211>648</s211>
<s212>DNA</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic oligonucleotide, Antibody G2 heavy
      chain</s223>
</s220>
</s200>
<s400> 31
gaggtccagc tgcagcagtc tggacctgag ctggtaaagc ctggggcttc agtgaagatg     60
tcctgcaagg cttctggata cacattcact agctctgtta tgcactgggt gaagcagaag    120
cctgggcagg gccttgagtg gattggatat attaatcctt acaatgatgg tactaagtac    180
aatgagaagt tcaaaggcaa ggccacactg acttcagaca aatcctccag cacagcctac    240
atggaactca gcagcctgac ctctgaggac tctgcggtct attactgtgc aaaagggggt    300
aacgatggct actggggcca aggcactact ctcacagtct cctcagccaa aacgacaccc    360
ccatctgtct atccactggc ccctggatct gctgcccaaa ctaactccat ggtgaccctg    420
ggatgcctgg tcaagggcta tttccctgag ccagtgacag tgacctggaa ctctggatcc    480
ctgtccagcg gtgtgcacac cttcccagct gtcctgcagt ctgacctcta cactctgagc    540
agctcagtga ctgtcccctc cagcacctgg cccagcgaga ccgtcacctg caacgttgcc    600
cacccggcca gcagcaccaa ggtggacaag aaaattgtgc ccagggat                 648
</s400>
<s200>
<s210>32</s210>
<s211>648</s211>
<s212>DNA</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic oligonucleotide, Antibody G2 light
      chain</s223>
</s220>
</s200>
<s400> 32
gaaattgtgc tcacccagtc tccaaccacc atggctgcat ctcccgggga gaagatcact     60
atcacctgta gtgccagctc aagtataagt tccatttact tgcattggta tcagcagaag    120
ccaggattct cccctaaagt cttgatttat agggcatcca atctggcttc tggagtccca    180
gctcgcttca gtggcagtgg gtctgggacc tcttactctc tcacaattgg caccatggag    240
gctgaagatg ttgccactta ctactgccag cagggtagta ctataccatt cacgttcggc    300
tcggggacaa agttggaaat aaaacgggct gatgctgcac caactgtatc catcttccca    360
ccatccagtg agcagttaac atctggaggt gcctcagtcg tgtgcttctt gaacaacttc    420
taccccagag acatcaatgt caagtggaag attgatggca gtgaacgaca aaatggtgtc    480
ctgaacagtt ggactgatca ggacagcaaa gacagcacct acagcatgag cagcaccctc    540
acattgacca aggacgagta tgaacgacat aacagctata cctgtgaggc cactcacaag    600
acatcaactt cacccatcgt caagagcttc aacaggaatg agtgttaa                 648
</s400>
<s200>
<s210>33</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 Chothia CDR
      H1</s223>
</s220>
</s200>
<s400> 33
Gly Phe Thr Phe Ser Asn Tyr
1               5
</s400>
<s200>
<s210>34</s210>
<s211>5</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 Kabat CDR
      H1</s223>
</s220>
</s200>
<s400> 34
Asn Tyr Trp Ile Ser
1               5
</s400>
<s200>
<s210>35</s210>
<s211>8</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G1 Chothia CDR
      H2</s223>
</s220>
</s200>
<s400> 35
Arg Ser Glu Ser Asp Ala Ser Ala
1               5
</s400>
<s200>
<s210>36</s210>
<s211>10</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 extended CDR
      H1</s223>
</s220>
</s200>
<s400> 36
Gly Tyr Thr Phe Thr Ser Ser Val Met His
1               5                   10
</s400>
<s200>
<s210>37</s210>
<s211>7</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 Chothia CDR
      H1</s223>
</s220>
</s200>
<s400> 37
Gly Tyr Thr Phe Thr Ser Ser
1               5
</s400>
<s200>
<s210>38</s210>
<s211>6</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide, Antibody G2 Chothia CDR
      H2</s223>
</s220>
</s200>
<s400> 38
Asn Pro Tyr Asn Asp Gly
1               5
</s400>
<s200>
<s210>39</s210>
<s211>5</s211>
<s212>PRT</s212>
<s213>Artificial sequence</s213>
<s220>
<s223>Synthetic polypeptide</s223>
</s220>
</s200>
<s400> 39
Gly Ser Lys Ala Phe
1               5
</s400>
</sequence-list-new-rules>
</sequence-cwu>
